⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IKT News
Inhibikase Therapeutics, Inc. Common Stock
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
IKT
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
globenewswire.com
IKT
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
globenewswire.com
IKT